CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cel-Sci Corporation

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia-Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
CEL-SCI Announces Closing of $2.5 Million Offering
CEL-SCI Announces Pricing of $2.5 Million Offering
CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review-in Talks with Potential Partners Interested in Commercialization of Multikine
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.